AURX OTC
Nuo Therapeutics, Inc.
1W: -2.3%
1M: +9.7%
3M: +23.8%
YTD: -37.5%
1Y: -35.9%
3Y: +4.2%
5Y: +177.8%
$1.25
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$60.5M
52W Range0.77-3.23
Volume800
Avg Volume3,091
Beta-104.09
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEODavid E. Jorden
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2017-10-24
Websitenuot.com
8285 El Rio
Houston, TX 77054
US
Houston, TX 77054
US
346 396 4770
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| JORDEN DAVID EMERSON | P-Purchase | 7,984 | $1.09 | 2026-08-28 |
| JORDEN DAVID EMERSON | A-Award | 7,984 | $1.09 | 2026-08-28 |
| JORDEN DAVID EMERSON | P-Purchase | 789 | $1.07 | 2026-08-27 |
| JORDEN DAVID EMERSON | A-Award | 789 | $1.07 | 2026-08-27 |
| WINZER C ERIC | M-Exempt | 40,000 | $1.00 | 2026-06-30 |